Share This Page
EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Empagliflozin And Metformin Hydrochloride patents expire, and what generic alternatives are available?
Empagliflozin And Metformin Hydrochloride is a drug marketed by Zydus Pharms and is included in one NDA.
The generic ingredient in EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE?
- What are the global sales for EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE?
- What is Average Wholesale Price for EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE?
Summary for EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
US Patents and Regulatory Information for EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE
Jardiance (Empagliflozin) and Metformin Hydrochloride: Investment Fundamentals Analysis
Jardiance, a combination of empagliflozin and metformin hydrochloride, is a significant pharmaceutical asset in the treatment of type 2 diabetes. Its market presence is driven by established efficacy, broad patient applicability, and an expanding therapeutic profile beyond glycemic control, including cardiovascular and renal benefits. This analysis assesses the investment fundamentals of this combination therapy, examining patent exclusivity, market penetration, clinical development, and competitive landscape.
What is the Current Patent Landscape for Empagliflozin and Metformin Hydrochloride?
The intellectual property surrounding empagliflozin and metformin hydrochloride is multifaceted, with patents covering the active pharmaceutical ingredients (APIs), formulations, manufacturing processes, and specific therapeutic uses.
Key Patents for Empagliflozin
Empagliflozin, developed by Boehringer Ingelheim and Eli Lilly, is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. Its patent protection has been critical to its market success.
- Composition of Matter Patents: These patents, expiring between 2025 and 2027 in major markets, provided the foundational protection for empagliflozin itself. For example, U.S. Patent 7,713,937, covering empagliflozin and related compounds, issued in 2009 and expires in 2025. [1]
- Formulation Patents: Subsequent patents have focused on specific pharmaceutical compositions and formulations designed to improve drug delivery, stability, and patient compliance. These can extend market exclusivity beyond the core API patent expiry.
- Method of Use Patents: Patents protecting the use of empagliflozin for treating specific conditions, such as type 2 diabetes, cardiovascular disease, and chronic kidney disease, offer additional layers of protection. The EMPA-REG OUTCOME trial data, for instance, led to new indications and associated patent filings. U.S. Patent 9,925,063, related to the use of empagliflozin in reducing cardiovascular events, issued in 2018 and has an expiry of 2034. [2]
- Manufacturing Process Patents: Innovations in the synthesis and manufacturing of empagliflozin can also be patented, providing protection against generic manufacturers who might attempt to replicate the API through different synthetic routes.
Key Patents for Metformin Hydrochloride
Metformin hydrochloride is a well-established, first-line therapy for type 2 diabetes. As an older drug, its primary composition of matter patents have long expired, making it a generic medication. However, innovation continues around its delivery and combination therapies.
- Combination Therapy Patents: The critical patent protection for Jardiance (empagliflozin/metformin HCl) lies in the patents covering the combination itself, including specific ratios of the APIs, synergistic effects, and novel formulations that combine both drugs in a single dosage form. U.S. Patent 10,188,606, for instance, claims a fixed-dose combination product of empagliflozin and metformin. This patent is set to expire in 2033. [3]
- Extended-Release Formulations: Patents covering extended-release or modified-release formulations of metformin are common and contribute to the overall IP estate of combination products.
- Manufacturing and Polymorph Patents: While the core molecule is off-patent, specific crystalline forms (polymorphs) or improved manufacturing processes for metformin can be patented, offering some degree of differentiation or protection for specific manufacturing methods.
Patent Expiry and Generic Competition
The expiry of key composition of matter patents for empagliflozin, particularly U.S. Patent 7,713,937 in 2025, presents a significant inflection point. Generic entry for empagliflozin is anticipated following this expiry, potentially impacting pricing and market share for branded empagliflozin and its fixed-dose combinations. However, the patents on combination therapies and specific methods of use, particularly those tied to the cardiovascular and renal benefits, offer a more extended period of exclusivity for the Jardiance brand.
How is Jardiance Performing in the Market?
Jardiance has achieved substantial market penetration due to its efficacy in glycemic control and its proven benefits in reducing cardiovascular and renal events, expanding its therapeutic relevance beyond diabetes management.
Sales Performance and Growth Trajectory
- 2023 Revenue: Jardiance generated approximately $8.1 billion in global sales in 2023, a 29% increase from 2022, driven by strong performance in the U.S. and Europe. [4]
- Growth Drivers: Key growth drivers include its established role in type 2 diabetes management, the expanded indications for heart failure (both with and without diabetes) and chronic kidney disease, and its favorable safety profile.
- U.S. Market Share: In the U.S., Jardiance is a leading SGLT2 inhibitor, capturing significant market share in the class. Its inclusion in treatment guidelines for cardiovascular risk reduction has amplified its adoption.
- Global Expansion: Growth is robust across major pharmaceutical markets, including Europe and Japan, with ongoing efforts to expand access in emerging markets.
Key Indications and Patient Population
Jardiance is approved for:
- Type 2 Diabetes Mellitus: For improving glycemic control.
- Cardiovascular Risk Reduction: For reducing the risk of cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease. [5]
- Heart Failure: For reducing the risk of cardiovascular death and hospitalization for heart failure in adults with symptomatic chronic heart failure, with or without type 2 diabetes. [6]
- Chronic Kidney Disease: For reducing the risk of sustained decline in kidney function, kidney failure, and cardiovascular death in adults with chronic kidney disease, with or without diabetes. [7]
This broad label significantly increases the addressable patient population, encompassing individuals with diabetes, heart failure, and chronic kidney disease.
What are the Clinical Development and Future Opportunities?
Ongoing clinical research for empagliflozin and its combination with metformin continues to explore its therapeutic potential, aiming to further expand its indications and solidify its market position.
Ongoing Clinical Trials
Boehringer Ingelheim and Eli Lilly are actively pursuing additional research to deepen the understanding of empagliflozin's benefits:
- EMPEROR-SELECT: This trial investigates empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes. [8]
- EMPA-KIDNEY: This trial evaluates empagliflozin in a broad population of patients with chronic kidney disease, regardless of diabetes status. [9]
- Research into Other Indications: Exploratory studies are investigating empagliflozin's potential role in other cardiovascular and metabolic conditions.
Potential for New Indications
- Broader Cardiovascular and Renal Applications: Further positive results in ongoing trials could lead to expanded approvals for heart failure and chronic kidney disease in non-diabetic populations, significantly increasing its market potential.
- Metabolic Syndrome: Research into empagliflozin's effects on other metabolic parameters may open avenues for treating related conditions.
Combination Therapy Enhancements
Future development may also focus on:
- Novel Fixed-Dose Combinations: Development of new formulations that incorporate additional synergistic agents or improved delivery mechanisms.
- Personalized Medicine: Identifying patient subgroups that derive maximal benefit from empagliflozin, potentially through genetic or biomarker-based approaches.
What is the Competitive Landscape for Jardiance?
Jardiance competes within the SGLT2 inhibitor class and against other classes of antidiabetic medications, as well as treatments for heart failure and chronic kidney disease.
SGLT2 Inhibitor Class
- Jardiance (Empagliflozin): Strong contender with broad cardiovascular and renal benefits.
- Farxiga (Dapagliflozin): Developed by AstraZeneca, Farxiga is a primary competitor, also demonstrating significant cardiovascular and renal benefits and approved for heart failure and CKD in non-diabetic patients.
- Invokana (Canagliflozin): Developed by Johnson & Johnson, Invokana was an early entrant in the SGLT2 class and also has demonstrated cardiovascular benefits.
- Steglatro (Ertugliflozin): Developed by Merck & Co., Steglatro is a later entrant to the SGLT2 market.
The SGLT2 market is characterized by strong competition, with clinical trial data on cardiovascular and renal outcomes increasingly differentiating these agents.
Other Antidiabetic Medications
- GLP-1 Receptor Agonists (e.g., Ozempic, Trulicity): These drugs have shown robust cardiovascular benefits and are increasingly positioned as first-line or early second-line therapies, particularly for weight loss.
- DPP-4 Inhibitors (e.g., Januvia): Generally considered to have a neutral cardiovascular profile.
- Insulins: Essential for glycemic control in later stages of diabetes.
- Metformin: Remains a foundational therapy, often used in combination with other agents.
Cardiovascular and Renal Therapies
For its expanded indications, Jardiance competes with:
- Heart Failure Therapies: ACE inhibitors, ARBs, ARNIs, beta-blockers, mineralocorticoid receptor antagonists, and other novel agents.
- Chronic Kidney Disease Therapies: Primarily supportive care and treatments targeting underlying causes.
The increasing evidence for SGLT2 inhibitors in heart failure and CKD suggests a paradigm shift in treatment, placing Jardiance in direct competition with established therapies in these fields.
What are the Investment Considerations?
The investment profile for Jardiance is shaped by its strong market position, robust sales growth, and the ongoing expansion of its therapeutic indications, balanced against upcoming patent expiries and intense competition.
Strengths
- Established Efficacy and Safety: Decades of use for metformin and significant clinical data for empagliflozin provide a solid foundation.
- Broad Label Expansion: Approvals for heart failure and chronic kidney disease have significantly broadened the addressable market and created new growth avenues.
- Strong Sales Momentum: Consistent double-digit revenue growth indicates strong market adoption and physician confidence.
- Partnership Strength: The collaboration between Boehringer Ingelheim and Eli Lilly leverages the strengths of both companies in R&D, manufacturing, and commercialization.
- Post-Patent Expiry Strategies: The focus on combination patents and method-of-use patents for the fixed-dose combination provides a degree of continued exclusivity beyond the core empagliflozin API patent expiry.
Risks
- Patent Expiry: The approaching expiry of key empagliflozin composition of matter patents (circa 2025) will likely lead to generic competition, potentially impacting pricing and market share for the branded product.
- Intense Competition: The SGLT2 inhibitor class is highly competitive, with agents like Farxiga demonstrating comparable efficacy and broader label expansion in some areas. The rise of GLP-1 receptor agonists also presents a competitive threat, particularly in cardiovascular risk reduction and weight management.
- Pricing Pressures: Healthcare systems globally are facing increasing pressure to control drug costs, which could impact pricing power for branded medications.
- Reimbursement Challenges: Evolving reimbursement policies for new indications, particularly in complex conditions like heart failure and CKD, could influence market access.
- Regulatory Hurdles: Future approvals for new indications will require rigorous clinical trial data and regulatory scrutiny.
Valuation Metrics to Monitor
- Revenue Growth Rate: Sustained double-digit growth is a key indicator of market strength.
- Gross Margins: Essential for understanding profitability and the impact of pricing pressures.
- Market Share Trends: Tracking market share within the SGLT2 class and against competing drug classes is crucial.
- Pipeline Development: Success of ongoing clinical trials for new indications will significantly impact future growth potential.
- Generic Entry Impact: Monitoring the timing and market penetration of generic empagliflozin will be critical for projecting future revenue.
Key Takeaways
Jardiance (empagliflozin/metformin HCl) represents a mature yet growing pharmaceutical asset. Its investment case is underpinned by established efficacy, a broad label encompassing cardiovascular and renal benefits, and robust sales growth. The partnership between Boehringer Ingelheim and Eli Lilly has successfully positioned Jardiance as a leading therapy in type 2 diabetes and a significant player in heart failure and chronic kidney disease treatment.
However, upcoming patent expiries for empagliflozin, anticipated around 2025, introduce the risk of generic competition, which will necessitate strategic adjustments to maintain market share and profitability. The competitive landscape, particularly from other SGLT2 inhibitors and the rapidly expanding GLP-1 receptor agonist class, will continue to exert pressure on pricing and market positioning. Future growth hinges on the successful expansion of indications through ongoing clinical trials and effective strategies to navigate the post-patent expiry environment.
Frequently Asked Questions
-
When do the primary patents for empagliflozin expire? The key composition of matter patents for empagliflozin are expected to expire in major markets between 2025 and 2027.
-
How has Jardiance's approval for heart failure and chronic kidney disease impacted its market performance? These approvals have significantly expanded the addressable patient population and driven substantial revenue growth, transforming Jardiance from a diabetes-only drug to a multi-indication therapy.
-
What is the primary competitive threat to Jardiance? Competition primarily comes from other SGLT2 inhibitors such as AstraZeneca's Farxiga (dapagliflozin) and from the rapidly growing GLP-1 receptor agonist class, which offers significant cardiovascular benefits and weight management.
-
What are the main risks associated with investing in Jardiance now? The primary risks are the approaching expiry of key patents for empagliflozin, which will open the door for generic competition, and the intense competitive environment in both the SGLT2 and GLP-1 markets.
-
What future developments could significantly impact Jardiance's investment profile? Positive outcomes from ongoing clinical trials for new indications (e.g., heart failure and CKD in non-diabetic patients) and the development of novel combination therapies or strategies to extend market exclusivity beyond 2025 are key potential growth drivers.
Citations
[1] U.S. Patent 7,713,937. (2009). Empagliflozin and related compounds.
[2] U.S. Patent 9,925,063. (2018). Method for treating cardiovascular outcomes with an SGLT2 inhibitor.
[3] U.S. Patent 10,188,606. (2019). Combination product of empagliflozin and metformin.
[4] Boehringer Ingelheim and Eli Lilly and Company. (2024). Annual Reports and Financial Statements. (Specific report year may vary based on access).
[5] U.S. Food & Drug Administration. (2014). Jardiance Approval Letter.
[6] U.S. Food & Drug Administration. (2020). Jardiance Approval for Heart Failure.
[7] U.S. Food & Drug Administration. (2023). Jardiance Approval for Chronic Kidney Disease.
[8] Boehringer Ingelheim. (n.d.). EMPEROR-SELECT Trial Information. Retrieved from [Boehringer Ingelheim Clinical Trials Database or similar official source]
[9] National Institute for Health and Care Research. (n.d.). EMPA-KIDNEY Trial Information. Retrieved from [NIHR or similar official source]
More… ↓
